Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation

Ellie Coromilas, Em Claire Que-Xu, D'Vesharronne V. Moore, Tomoko S. Kato, Christina Wu, Ruiping Ji, Raymond Givens, Ulrich P. Jorde, Hiroo Takayama, Yoshifumi Naka, Isaac George, Donna Mancini, P. Christian Schulze

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Background: Galectin-3 is a marker of myocardial inflammation and fibrosis shown to correlate with morbidity and mortality in heart failure (HF). We examined the utility of galectin-3 as a marker of the severity of HF, the response of galectin-3 levels to ventricular assist device (LVAD) implantation or heart transplantation (HTx), and its use as a prognostic indicator. Methods: Plasma galectin-3 was measured using a commercially available ELISA assay in patients with stable HF (n = 55), severe HF (n = 63), at 3 (n = 17) and 6 (n = 14) months post-LVAD and at LVAD explantation (n = 23), patients following HTx (n = 85) and healthy controls (n = 30). Results: Galectin-3 levels increase with the severity of HF (severe HF: 28.2 ± 14, stable HF: 19.7 ± 13, p = 0.001; controls: 13.2 ± 9 ng/ml, p = 0.02 versus stable HF). Following LVAD implantation, galectin-3 levels are initially lower (3 months: 23.7 ± 9, 6 months: 21.7 ± 9 versus 29.2 ± 14 ng/ml implantation; p = NS) but are higher at explantation (40.4 ± 19 ng/ml; p = 0.005 versus pre-LVAD). Galectin-3 levels >30 ng/ml are associated with lower survival post-LVAD placement (76.5 % versus 95.0 % at 2 years, p = 0.009). After HTx, galectin-3 levels are lower (17.8 ± 7.1ng/ml post-HTx versus 28.2 ± 14 pre-HTx; p < 0.0001). Patients with coronary allograft vasculopathy (CAV) post-HTx showed higher galectin-3 levels (20.5 ± 8.8ng/ml versus 16.8 ± 6.3, p = 0.1) and the degree of CAV correlated with levels of galectin-3 (r 2 = 0.17, p < 0.0001). Conclusions: Galectin-3 is associated with the severity of HF, exhibits dynamic changes during mechanical unloading and predicts survival post-LVAD. Further, galectin-3 is associated with the development on CAV post-HTx. Galectin-3 might serve as a novel biomarker in patients with HF, during LVAD support and following HTx.

Original languageEnglish (US)
Article number138
JournalBMC Cardiovascular Disorders
Volume16
Issue number1
DOIs
StatePublished - Jun 14 2016
Externally publishedYes

Keywords

  • Coronary Allograft Vasculopathy
  • Galectin-3
  • Heart Failure
  • Heart Transplantation
  • LVAD

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation'. Together they form a unique fingerprint.

  • Cite this

    Coromilas, E., Que-Xu, E. C., Moore, DV. V., Kato, T. S., Wu, C., Ji, R., Givens, R., Jorde, U. P., Takayama, H., Naka, Y., George, I., Mancini, D., & Schulze, P. C. (2016). Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. BMC Cardiovascular Disorders, 16(1), [138]. https://doi.org/10.1186/s12872-016-0298-z